Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum

Human Gene Therapy

Volumn 23, Issue 2, 2012, Pages 210-217

  San Sebastian, Waldy ^a   Richardson, R Mark ^a   Kells, Adrian P ^a   Lamarre, Clementine ^a   Bringas, John ^a   Pivirotto, Philip ^a   Salegio, Ernesto A ^a   Dearmond, Stephen J ^a   Forsayeth, John ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; GADOTERIDOL; LEVODOPA; METIROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANNULA; CORPUS STRIATUM; CORRELATION ANALYSIS; FEMALE; GENE TARGETING; GENE VECTOR; MACACA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PUTAMEN; QUANTITATIVE ANALYSIS; SCORING SYSTEM;

ANIMALS; CATHETERIZATION; CAUDATE NUCLEUS; CORPUS STRIATUM; DEPENDOVIRUS; DOPA DECARBOXYLASE; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; NEURONS; PUTAMEN; STEREOTAXIC TECHNIQUES; TRANSGENES;

MACACA MULATTA; PARKINSONIA; PRIMATES;

EID: 84856921721     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.162     Document Type: Article

References (33)

1. Bankiewicz, K.S., Oldfield, E.H., Chiueh, C.C., et al. (1986). Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39, 7-16. (Pubitemid 16090932)
2. Bankiewicz, K.S., Eberling, J.L., Kohutnicka, M., et al. (2000). Convection-enhanced delivery of AAV vector in parkinsonian monkeys: In vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. 164, 2-14. (Pubitemid 30490717)
3. Bankiewicz, K.S., Forsayeth, J., Eberling, J.L., et al. (2006). Longterm clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther. 14, 564-570. (Pubitemid 44296090)
4. Bartus, R.T., Herzog, C.D., Chu, Y., et al. (2011). Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains. Mov Disord 26, 27-36.
5. Binder, D.K., Rau, G.M., and Starr, P.A. (2005). Risk factors for hemorrhage during microelectrode-guided deep brain stimulator implantation for movement disorders. Neurosurgery 56, 722-732; discussion 722-732.
6. Bobo, R.H., Laske, D.W., Akbasak, A., et al. (1994). Convectionenhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U.S.A. 91, 2076-2080.
7. Christine, C.W., Starr, P.A., Larson, P.S., et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662-1669.
8. Ciesielska, A., Mittermeyer, G., Hadaczek, P., et al. (2011). Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol. Ther. 19, 922-927.
9. Daadi, M.M., Pivirotto, P., Bringas, J., et al. (2006). Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys. Neuroreport 17, 201-204. (Pubitemid 43100327)
10. Eberling, J.L., Jagust, W.J., Taylor, S., et al. (1998). A novel MPTP primate model of Parkinson's disease: Neurochemical and clinical changes. Brain Res. 805, 259-262. (Pubitemid 29005142)
11. Eberling, J.L., Jagust, W.J., Christine, C.W., et al. (2008). Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70, 1980-1983.
12. Feekes, J.A., and Cassell, M.D. (2006). The vascular supply of the functional compartments of the human striatum. Brain 129, 2189-2201. (Pubitemid 44289081)
13. Fiandaca, M., Forsayeth, J., Dickinson, P., and Bankiewicz, K. (2008). Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 5, 123-127. (Pubitemid 350299297)
14. Fiandaca, M., Varenika, V., Eberling, J., et al. (2009). Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage 47, T27-T35.
15. Forsayeth, J.R., Eberling, J.L., Sanftner, L.M., et al. (2006). A doseranging study of AAV-hAADC therapy in parkinsonian monkeys. Mol. Ther. 14, 571-577. (Pubitemid 44296089)
16. Gimenez, F., Krauze, M.T., Valles, F., et al. (2011). Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage 54(Suppl. 1), S189-S195.
17. Hadaczek, P., Eberling, J.L., Pivirotto, P., et al. (2010). Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol. Ther. 18, 1458-1461.
18. Imbert, C., Bezard, E., Guitraud, S., et al. (2000). Comparison of eight clinical rating scales used for the assessment of MPTPinduced parkinsonism in the macaque monkey. J. Neurosci. Methods 96, 71-76. (Pubitemid 30125866)
19. Krauze, M.T., Saito, R., Noble, C., et al. (2005). Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J. Neurosurg. 103, 923-929. (Pubitemid 43194589)
20. Matsushita, T., Elliger, S., Elliiger, C., et al. (1998). Adenoassociated virus vectors can be efficiently produced without helper virus. Gene Ther. 5, 938-945. (Pubitemid 28371911)
21. Muramatsu, S., Fujimoto, K., Kato, S., et al. (2010). A phase I study of aromatic l-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther. 18, 1731-1735.
22. Richardson, R.M., Varenika, V., Forsayeth, J.R., and Bankiewicz, K.S. (2009). Future applications: Gene therapy. In Intraoperative MRI in Functional Neurosurgery. P.S. Larson and D.A. Lim, eds. (W. B. Saunders, Philadelphia, PA) pp. 219-224.
23. Richardson, R.M., Kells, A.P., Martin, A.J., et al. (2011a). Novel platform for MRI-guided convection-enhanced delivery of therapeutics: Preclinical validation in nonhuman primate brain. Stereotact. Funct. Neurosurg. 89, 141-151.
24. Richardson, R.M., Kells, A.P., Rosenbluth, K.H., et al. (2011b). Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol. Ther. 19, 1048-1057.
25. Sanchez-Pernaute, R., Harvey-White, J., Cunningham, J., and Bankiewicz, K.S. (2001). Functional effect of adeno-associated virus mediated gene transfer of aromatic l-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol. Ther. 4, 324-330. (Pubitemid 33040517)
26. Song, D.K., and Lonser, R.R. (2008) Convection-enhanced delivery for treatment of pediatric neurologic disorders. J. Child. Neurol. 23, 1231-1237.
27. Su, X., Kells, A.P., Huang, E.J., et al. (2009). Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum. Gene Ther. 20, 1627-1640.
28. Valles, F., Fiandaca, M.S., Eberling, J.L., et al. (2010). Qualitative imaging of adeno-associated virus serotype 2-human aromatic l-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery 67, 1377-1385.
29. Varenika, V., Kells, A.P., Valles, F., et al. (2009). Controlled dissemination of AAV vectors in the primate brain. Prog. Brain Res. 175, 163-172.
30. Wright, J., Qu, G., Tang, C., and Sommer, J. (2003). Recombinant adeno-associated virus: Formulation challenges and strategies for a gene therapy vector. Curr. Opin. Drug Discov. Dev. 6, 174-178. (Pubitemid 36368371)
31. Yin, D., Valles, F.E., Fiandaca, M.S., et al. (2009). Striatal volume differences between non-human and human primates. J. Neurosci. Methods 176, 200-205.
32. Yin, D., Richardson, R.M., Fiandaca, M.S., et al. (2010). Cannula placement for effective convection-enhanced delivery in the non-human primate thalamus and brainstem: Implications for clinical delivery of therapeutics. J. Neurosurg. 113, 240-248.
33. Yin, D., Valles, F.E., Fiandaca, M.S., et al. (2011). Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage 54(Suppl. 1), S196-S203.